论文部分内容阅读
目的:分析左炔诺孕酮宫内节育系统(LNG-IUS)对他莫昔芬治疗的绝经前乳腺癌患者子宫内膜病变的影响。方法:选择杭州市萧山区第一人民医院2014年6月至2016年6月诊治的符合纳入标准的乳腺癌患者84例，采用随机数字表法分为放置LNG-IUS组(治疗组，n n＝39)和不放置LNG-IUS组(对照组，n n＝45)。治疗前行一般状况评估，治疗前、治疗后1年、治疗后2年行子宫内膜厚度检查、血脂检查、宫腔镜检查、子宫内膜病理类型分析、子宫内膜雌激素/孕激素受体表达测定并比较。n 结果:治疗前，两组一般情况、宫腔情况差异均无统计学意义(均n P>0.05)。治疗后1年，治疗组子宫内膜息肉发生率、子宫内膜增生/分泌期改变发生率、良性病变发生率、萎缩子宫内膜发生率分别为2.6%、5.1%、15.4%、76.9%，对照组分别为6.7%、20.0%、17.8%、55.6%，两组子宫内膜增生/分泌期改变发生率、萎缩子宫内膜发生率差异均有统计学意义(χn 2＝4.06、4.22，均n P<0.05)；治疗后2年，治疗组子宫内膜息肉发生率、子宫内膜增生/分泌期改变发生率、萎缩子宫内膜发生率分别为0.0%、2.6%、84.6%，对照组分别为11.1%、15.6%、60.0%，两组差异均有统计学意义(χn 2＝4.608、4.092、6.203，均n P0.05). After 1 year, the incidences of endometrial polyp, endometrial hyperplasia/secretion, benign lesion and endometrial atrophy in the treatment group were 2.6%, 5.1%, 15.4%, 76.9%, respectively, which in the control group were 6.7%, 20.0%, 17.8%, 55.6%, respectively.the differences between the two groups were statistically significant(χn 2=4.06, 4.22, all n P<0.05). After 2 years, the incidences of endometrial polyp, endometrial hyperplasia/secretion, benign lesion and endometrial atrophy in the treatment group were 0.0%, 2.6%, 84.6%, respectively, which in the control group were 11.1%, 15.6%, 60.0%, respectively, the differences between the two groups were statistically significant(χn 2=4.608, 4.092, 6.203, all n P<0.05).n Conclusion:LNG-IUS can prevent the benign endometrial lesions of breast cancer patients caused by tamoxifen therapy after surgery, and can decrease the incidence of endometrial polyp and endometrial hyperplasia/secretion, while increase the incidence of endometrial atrophy, without increasing the recurrence risk of breast cancer.